| PDF (561kB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-269867
- DOI to cite this document:
- 10.5283/epub.26986
Alternative links to fulltext:Pubmed
Abstract
The cardiovascular and endocrine profile of cromakalim has been studied in 8 healthy men (age 25 +/- 2 years: means SEM) and its influence on renin release from cultured rat juxtaglomerular cells in vitro has also been examined. According to a double-blind, randomized sequence the subjects received placebo or cromakalim 1 mg as a single daily oral dose for 5 days. Compared to placebo, cromakalim ...

Owner only: item control page